Posts tagged TC Heartland.
Blogs
3 minute read
Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S. In practice, most suits have been filed in Delaware and New Jersey, with suits against multiple generic companies over the same drug consolidated in one proceeding.
In November 2020, the Federal Circuit upended this settled practice when it issued its opinion in Valeant Pharmaceuticals v. Mylan Pharmaceuticals, No. 19-2402 (Fed. Cir. 2020), holding that venue is not established by contemplated future acts of ...
Blog Editors
Recent Updates
- Sentencing Commission Seeks Public Input on Amendments to Fraud Sentencing Guidelines
- Agentic AI’s Next Iteration: From Super-AIs to Teams of Specialized Agents — and What It Means for Law & Business
- Divided Court Clarifies Limits on Federal Habeas Appeals - SCOTUS Today
- A Pattern of Uncertainty: Judicial Decision-Making During Federal Shutdowns
- Navigating FDA’s Stance on DSHEA Disclaimer Placement